Inventor · disambiguated record
Rachida Siham Bel Aiba
Also filed as: BEL AIBA RACHIDA · BEL AIBA RACHIDA SIHAM
16 granted patents·5 pending applications·29 citations·filing 2016–2022
89Inventor score
Top patents by PatentIndex Score
21 records- 0192US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0289US10273275B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 30, 2019·10 cites·20 claims
- 0387US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 0485US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 0583US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 0682US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 0780US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 0875US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 0974US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 1072US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 1171US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 1271US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 1363US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 1460US10787491B2Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Sep 29, 2020·0 cites·11 claims
- 1559US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 1652US2017369542A1Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding suchPIERIS PHARMACEUTICALS GMBH·Filed 2017·Application pending·0 cites
- 1750US2023366884A1Biomarker methods and usesPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 1847US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 1945US12486330B2Fusion proteins specific for CD137 and GPC3PIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Dec 2, 2025·0 cites·6 claims
- 2036US2019010231A1Novel fusion polypeptide specific for lag-3 and pd-1PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 2135US10703810B2Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)PIERIS AUSTRALIA PTY LTD·Filed 2016·Granted Jul 7, 2020·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →